Lucia Sisic, a Vienna-based model who was named Miss Austria in 2024 and served as queen until her death, died at age 22, ...
A team from the Research Institute of the McGill University Health Center (The Institute) have created a three-dimensional, ...
YouTube on MSN
She beat sickle cell disease with CRISPR - now the FDA has approved the treatment for young children
A lifetime of sudden, crushing pain had already damaged Victoria Gray’s heart and repeatedly sent her to the emergency r ...
Chia seeds and flaxseeds offer similar benefits, but their nutritional differences may make one a better fit for your ...
More than 100 sick sea lions have been rescued this year, surpassing the Marine Mammal Center’s annual average.
Concurrent guideline statements have increased classification ambiguity, strengthening arguments for phenotype-first ...
Antonia Hoyle reflects on how the juggernaut weight-loss jab industry has affected everything from restaurants to airlines - ...
Meet Dr. Ross Butschek. St. John's Health's newest cardiologist, known to colleagues as "the cardiomyopathy guy." From heart failure to preventive care, he's here to help patients across the Tetons ...
Novo Nordisk halts Phase III ziltivekimab trials (HERMES, ATHENA) for heart failure after futility signal. Read the latest ...
Investigators at Cedars-Sinai Health Sciences University used an experimental drug to reverse the effects of systemic ...
Amgen (AMGN) stock drops after a phase 3 trial failure for a heart drug from Novartis (NVS) and Ionis Pharma (IONS). BMO Capital Markets downgrades. Read more here.
Novartis heart failure drug pelacarsen failed to reduce cardiovascular risk in a large trial despite lowering Lp(a) levels, Novartis announced.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results